CORT CORCEPT THERAPEUTICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1088856 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY30.0%
TTM net income YoY52.9%
TTM EPS YoY52.9%
Revenue 3-yr CAGR28.9%
Net income 3-yr CAGR21.1%
Margins
Gross margin98.5%
Operating margin11.5%
Net margin16.8%
FCF margin20.2%
EBITDA margin11.8%
Returns
ROE22.1%
ROA17.5%
ROIC (approx.)17.9%
Asset turnover1.04x
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.00x
Current ratio3.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.22x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $340.47M | $256.15M | $164.90M | $202.12M | $207.64M | $194.43M | $157.21M | $181.89M |
| Cost of revenue | $4.61M | $4.06M | $2.88M | $2.54M | $4.60M | $3.43M | $2.40M | $2.96M |
| Gross profit | $335.86M | $252.09M | $162.02M | $199.58M | $203.04M | $191.00M | $154.81M | $178.93M |
| R&D expense | $56.71M | $53.89M | $66.27M | $64.86M | $68.85M | $60.47M | $60.73M | $70.30M |
| SG&A expense | $164.43M | $156.90M | $145.36M | $130.24M | $123.98M | $103.85M | $90.66M | $83.37M |
| Operating income | $114.72M | $41.30M | -$49.60M | $4.49M | $10.22M | $26.68M | $3.42M | $25.26M |
| Pretax income | $120.31M | $45.93M | -$44.72M | $9.91M | $15.24M | $31.69M | $9.62M | $31.96M |
| Income tax | -$6.47M | $2.94M | -$12.95M | -$14.38M | -$4.42M | -$3.46M | -$10.93M | $1.21M |
| Net income | $126.78M | $42.99M | -$31.76M | $24.29M | $19.67M | $35.15M | $20.55M | $30.75M |
| EBITDA | $115.75M | $42.16M | -$49.00M | $4.78M | $10.70M | $27.14M | $3.88M | $25.54M |
| EPS (basic) | 1.17 | 0.40 | -0.30 | — | 0.19 | 0.33 | 0.19 | — |
| EPS (diluted) | 1.01 | 0.36 | -0.30 | — | 0.16 | 0.29 | 0.17 | — |
| Weighted avg. shares (diluted) | 123.20M | 118.39M | 104.44M | — | 119.44M | 120.48M | 119.82M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $98.72M | $111.04M | $108.74M | $120.50M | $125.14M | $102.75M | $89.82M | $128.66M |
| Short-term investments | $271.98M | $197.16M | $229.45M | $251.66M | $296.55M | $239.48M | $232.94M | $255.67M |
| Receivables | $111.06M | $76.92M | $39.07M | $59.79M | $69.63M | $64.57M | $61.82M | $53.98M |
| Inventory | $11.91M | $13.19M | $12.89M | $12.87M | $12.35M | $12.28M | $14.37M | $12.41M |
| Current assets | $533.87M | $439.68M | $426.03M | $485.46M | $541.13M | $443.11M | $438.50M | $471.60M |
| PP&E, net | $4.94M | $5.13M | $3.17M | $1.89M | $2.09M | $2.35M | $2.54M | $2.69M |
| Total assets | $1.03B | $888.70M | $814.88M | $836.65M | $823.61M | $801.72M | $846.46M | $840.55M |
| Current liabilities | $177.68M | $153.80M | $149.19M | $166.09M | $172.26M | $144.66M | $143.07M | $140.77M |
| Total liabilities | $200.29M | $182.93M | $176.89M | $188.85M | $191.71M | $165.93M | $163.17M | $160.96M |
| Shareholders' equity | $833.74M | $705.78M | $637.99M | $647.80M | $631.90M | $635.79M | $683.28M | $679.59M |
| Shares outstanding | — | — | — | 105.97M | — | — | — | 105.11M |
| Cash flow statement | ||||||||
| Operating cash flow | $142.89M | $33.54M | -$16.77M | $38.45M | $54.48M | $43.94M | $4.77M | $60.06M |
| Capital expenditure | $709,000 | $2.53M | $201,000 | $50,000 | $0 | $57,000 | $104,000 | $121,000 |
| Free cash flow | $142.18M | $31.02M | -$16.97M | $38.40M | $54.48M | $43.88M | $4.67M | $59.94M |
| Investing cash flow | -$131.99M | -$29.24M | $4.54M | -$11.84M | $14.64M | $70.13M | -$3.17M | -$64.36M |
| Financing cash flow | -$23.89M | -$2.04M | $760,000 | -$31.22M | -$46.41M | -$102.93M | -$39.80M | -$4.56M |
| Depreciation & amortization | $1.03M | $863,000 | $598,000 | $289,000 | $477,000 | $469,000 | $462,000 | $281,000 |
| Stock-based compensation | $29.44M | $29.42M | $23.04M | $20.77M | $22.88M | $19.02M | $21.83M | $16.80M |
| Share buybacks | $5.75M | $0 | $0 | $0 | $42.46M | $103.02M | $27.43M | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.